Treatment News : Janssen Files for Approval of Single-Pill Prezista & Cobicistat

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 1, 2014

Janssen Files for Approval of Single-Pill Prezista & Cobicistat

Janssen Research & Development has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for a once-daily fixed dose combination tablet of two HIV antiretrovirals (ARVs): the company’s Prezista (darunavir) and Gilead Sciences’ cobicistat. Prezista is a protease inhibitor, and cobicistat is an investigational pharmacokinetic enhancer, also known as a boosting agent, that, like Norvir (ritonavir), can increase the level of absorption into the blood of other ARVs and thus make them more effective.

Prezista is already FDA approved for the treatment of HIV-1 in both treatment-naive and treatment-experienced adults who have no resistance mutations to the drug. Since June 2011, Janssen has been working under a licensing agreement with Gilead to develop this new combination pill. If the tablet is approved, it will be marketed under a new name.

“[Prezista] is the most prescribed HIV protease inhibitor in the United States, and we are excited to be taking this important step in our efforts to offer it with an alternative boosting agent in a fixed-dose combination tablet,” Johan van Hoof, MD, therapeutic area head of infectious diseases and vaccines at Janssen, said in a release. “This filing demonstrates our ongoing commitment to develop new HIV treatment options and fixed-dose treatment regimens for those living with the disease.”

To read the Janssen press release, click here.

Search: Janssen, Gilead Sciences, New Drug Application, Prezista, darunavir, cobicistat, Norvir, ritonavir


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.